Live Breaking News & Updates on Molecular diagnostics program
Stay updated with breaking news from Molecular diagnostics program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hubble's Latest Image Release Is So Beautiful, It Should Be Illegal Just audacity. The absolute cheek of it. Here you were, just minding your own mundane business, and then Hubble had to come along and remind you that our Universe is jaw-droppingly, mind-blowingly, sickeningly gorgeous.
What you're looking at is a nebula around 4,900 light-years away in the constellation of Gemini. It's named AFGL 5180, and it's part of a vast molecular cloud complex named Gem OB1. Such thick molecular clouds are where stars are born, and AFLG 5180 is no exception. It's spectacularly lit from within by a very young, hot star that's violently disturbing the space around it as it grows, carving out vast cavities in the gas cloud.
Molecular Partners AG: Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 11, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin ® therapeutics, today announced the nomination of Agnete Fredriksen, Ph.D., to the Company's Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021. "We are pleased to propose Agnete for election to our Board of Directors during a time of growth and development for Molecular Partners, as we lay the foundations for an infectious diseases portfolio and new technologies for next-generation cancer immunotherapies to fruition," said Bill Burns, chairman of the Molecular Partners Board of Directors. "We look forward to benefiting from her breadth of expertise across our deepening portfolio as we continue to expand the capabilities of our DARPin
Mar 11 2021 Read 205 Times Author: Robert P. Rambo on behalf of Diamond Light Source Ltd Free to read Unlock In 2020, the most significant application of Soft-condensed matter (SCM) science was, undoubtedly, the development of the COVID vaccines by Pfizer-BioNTech and Moderna which are composed of a synthetic messenger RNA encapsulated within a lipid nanoparticle [1]. SCM science drives continued improvements to quality of life as SCM science is integral to a broad range of industrial sectors. These sectors include food safety and waste, agriculture, polymers, coatings, additive manufacturing, lubricants and additives, personal care, electronics, energy storage, transportation, health and medicine. SCM materials occur over a range of physical states that include liquid, semi-solid, waxes, glasses and aerosols. This necessitates a complementary and diverse suite of instrumentation and methodologies for understanding how molecular details give rise to the desired macroscopic, bulk properties of the material. Diamond Light Source, operating since 2007, is the United Kingdom’s synchrotron light source and provides four instruments (beamlines) for investigating SCM materials: B21 (high-throughput small-angle X-ray scattering for liquids), B22 (infrared nanospectroscopy and imaging), B23 (ultra-violet circular dichroism spectroscopy) and I22 (general purpose small angle X-ray scattering and diffraction for non-crystalline materials).
(2) ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15, 2021. The accepted research describes multiple aspects of validation for the unique mechanisms of these therapies in development for treating a wide range of tumor types. Accepted abstract titles include: MP0317 (targeting CD40 and FAP) MP0317, a FAPxCD40 targeting multi-specific DARPin® therapeutic, drives immune activation and leads to macrophage repolarization in vitro and ex vivo
Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers Predictable exposure seen post administration, confirming the expected half-life of 2-3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers. In the placebo-controlled phase 1 study, healthy volunteers were randomized 3:1 to receive an infusion of ensovibep, or placebo, respectively. Two dosing cohorts have been fully enrolled and received a single infusion of 3mg or 9mg per kilogram body weight, with 8 patients per dose cohort (16 total: 12 active, 4 placebo). In each of these cohorts, ensovibep was seen to be safe and well tolerated, with no significant adverse events reported. Preliminary results showed extended exposure of the DARPin® candidate in serum, with a half-life of 2-3 weeks, as was expected from preclinical experiments. These data confirm the systemic administration of a multi-specific DARPin® antiviral therapy to be safe and well tolerated, and support advanced plans for additional clinical work in positively diagnosed patients.
Mar 02 2021 Read 592 Times Labs are increasingly choosing INTEGRA Biosciences’ liquid handling instruments to help them address growing workloads associated with Human papilloma virus (HPV) screening. Several studies have recently suggested that PCR-based screening is more accurate and offers earlier detection of pre-cancerous growths than the conventional Papanicolaou (Pap) test and liquid-based cytology, leading to a gradual shift towards molecular diagnostics approaches. The ASSIST PLUS pipetting robot is ideally suited to this type of diagnostic screening workflow, offering fast and easy, walkaway automation of protocols. The Centre de Pathologie du Maine Normandie (CPMN) in Le Mans was the first lab in France to install an ASSIST PLUS to process HPV samples, and this system has now been adopted by several labs nationally. Nucleic acid extraction and PCR set-up are combined into a single program on the ASSIST PLUS, significantly simplifying the workflow and ensuring superior reproducibility with error-free pipetting. Dr Quentin Breton, a pathologist at CPMN, commented: “We chose the ASSIST PLUS because we wanted a solution that would allow us to automate the protocol for HPV testing as much as possible, while maintaining strict quality requirements and avoiding pipetting errors. It has now become an integral part of management of our HPV samples, and we have ideas on how to implement it for several other molecular biology workflows.”
(1) Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular and genetic diagnostics, Frost & Sullivan recognizes Sunquest Information Systems with the 2021 North America Company of the Year Award. Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum. In particular, its Sunquest Mitogen LIMS drives a superior user experience with its built-in audit trails, patient-centric focus, support for multiple workflows and instruments, and adaptability to client needs.
DGAP-News: Molecular Health GmbH: Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel PMS2, respectively. Therefore, testing BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient's individual risk of developing cancer [1],[2], and as a predictive biomarker and companion diagnostic test for certain drugs [3]. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole-exome or whole-genome data, so that many different hereditary diseases can be identified at once. "With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention", said Christian Meisel, MD, PhD, Chief Medical Officer at Molecular Health.
Message : Required fields Data in Twenty-One Poster and Oral Presentations Highlight use of GeoMx Digital Spatial Profiler and the Spatial Molecular Imager Platform for Discovery and Translational Applications NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of a Technology Access Program (TAP) for the Spatial Molecular Imager. Under the program, a customer can submit tissue samples to NanoString to be analyzed using the 1000-plex RNA panel and receive a complete data package. Researchers interested in participating in NanoString’s Technology Access Program should contact the company at TAP@nanostring.com.